Beijing Tiantan Biological Products (SHSE:600161) Total Liabilities : ¥1,605 Mil (As of Mar. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products Total Liabilities?

Beijing Tiantan Biological Products's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,605 Mil.

Beijing Tiantan Biological Products's quarterly Total Liabilities declined from Sep. 2023 (¥2,117.37 Mil) to Dec. 2023 (¥1,433.69 Mil) but then increased from Dec. 2023 (¥1,433.69 Mil) to Mar. 2024 (¥1,605.34 Mil).

Beijing Tiantan Biological Products's annual Total Liabilities increased from Dec. 2021 (¥1,310.77 Mil) to Dec. 2022 (¥1,573.60 Mil) but then declined from Dec. 2022 (¥1,573.60 Mil) to Dec. 2023 (¥1,433.69 Mil).

Beijing Tiantan Biological Products Total Liabilities Historical Data

The historical data trend for Beijing Tiantan Biological Products's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tiantan Biological Products Total Liabilities Chart

Beijing Tiantan Biological Products Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,137.05

1,554.25

1,310.77

1,573.60

1,433.69

Beijing Tiantan Biological Products Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,797.60	1,833.09	2,117.37	1,433.69	1,605.34

Beijing Tiantan Biological Products Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Beijing Tiantan Biological Products's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1279.62	+	(24.415	+	129.652
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,434

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	14188.057	-	12754.37
	=	1,434

Beijing Tiantan Biological Products's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1449.275	+	(27.51	+	128.55
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,605

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	14791.832	-	13186.497
	=	1,605

Beijing Tiantan Biological Products Total Liabilities Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tiantan Biological Products (SHSE:600161) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

No. 4 Sanjianfang South Li, Zhongdan Center, Beijing, CHN, 100024

Website

http://www.tiantanbio.com

Beijing Tiantan Biological Products Corp Ltd is a China-based company engaged in the research and development, manufacturing, sales and consulting services for blood products. The company's blood products include Shanghai Blood Human Albumin, Shanghai blood system intravenous injection of human immunoglobulin, Guizhou blood human albumin, Rongsheng human albumin, Guizhou blood system static injection immunoglobulin, Rongsheng tetanus human immunoglobulin and others.

Executives

Wang Jian Ming	Supervisors
Liu Ya Na	Directors, senior managers
Fu Dao Xing	Directors, senior managers
He Yan Lin	Directors, senior managers
Hu Li Gang	Director
Ci Xiang	senior management
Yang Hui Chuan	Director
Zhang Yi	senior management
Wu Zhen Shan	senior management

Beijing Tiantan Biological Products (SHSE:600161) Headlines

No Headlines